Martingale Asset Management L P boosted its holdings in Pfizer Inc. (NYSE:PFE) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,709,938 shares of the biopharmaceutical company’s stock after purchasing an additional 16,175 shares during the quarter. Pfizer comprises approximately 0.8% of Martingale Asset Management L P’s investment portfolio, making the stock its 10th largest holding. Martingale Asset Management L P’s holdings in Pfizer were worth $62,038,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. BlackRock Inc. grew its position in Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Pfizer by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after acquiring an additional 4,998,981 shares during the last quarter. Jensen Investment Management Inc. purchased a new position in Pfizer during the 2nd quarter worth $110,291,000. Neuberger Berman Group LLC boosted its holdings in Pfizer by 17.9% during the 1st quarter. Neuberger Berman Group LLC now owns 16,056,110 shares of the biopharmaceutical company’s stock worth $569,979,000 after acquiring an additional 2,432,694 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Pfizer by 4.4% during the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock worth $1,431,069,000 after acquiring an additional 1,671,311 shares during the last quarter. 68.96% of the stock is owned by institutional investors and hedge funds.
In related news, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the sale, the insider now directly owns 72,672 shares in the company, valued at approximately $2,979,552. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Pfizer Inc acquired 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The disclosure for this purchase can be found here. Insiders own 0.06% of the company’s stock.
A number of equities analysts have issued reports on the stock. Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price objective on shares of Pfizer in a report on Tuesday, August 28th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Independent Research set a $48.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, October 4th. Credit Suisse Group lifted their price objective on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Finally, Barclays reaffirmed a “neutral” rating and set a $40.00 price objective on shares of Pfizer in a report on Wednesday, September 26th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have issued a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and an average target price of $42.67.
NYSE PFE opened at $44.28 on Friday. The firm has a market cap of $264.31 billion, a PE ratio of 14.90, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 3 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Shares Bought by Martingale Asset Management L P” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/11/10/pfizer-inc-pfe-shares-bought-by-martingale-asset-management-l-p.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: How a Put Option Works
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.